Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.59 |
| ▸ | PI4KA | P42356 | 5/20 | 0.45 |
| ▸ | PI4K2B | Q8TCG2 | 5/20 | 0.45 |
| ▸ | PI4K2A | Q9BTU6 | 5/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | EIF4E | P06730 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3353317 | 0.98 | DYRK1A (0.57) | DYRK1API4KAPI4K2BPI4K2API4KB | |
| Formic Acid SCHEMBL31745015 | 0.89 | DYRK1A (0.49) | DYRK1API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL3386908 | 0.74 | DYRK1A (0.59) | DYRK1AMAP4K4EIF4EMKNK1MKNK2 | |
| SCHEMBL2078428 | 0.74 | DYRK1A (0.59) | DYRK1AEIF4EMKNK1MKNK2IRAK4 | |
| SCHEMBL32425027 | 0.74 | DYRK1A (1.00) | DYRK1AEIF4EMKNK1MKNK2IRAK4 | |
| SCHEMBL23158613 | 0.74 | DYRK1A (0.64) | DYRK1AEIF4EMKNK1MKNK2IRAK4 | |
| SCHEMBL1056424 | 0.74 | DYRK1A (0.59) | DYRK1AEIF4EMKNK1MKNK2IRAK4 | |
| SCHEMBL8223 | 0.74 | DYRK1A (1.00) | DYRK1AEIF4EMKNK1MKNK2IRAK4 | |
| SCHEMBL13186164 | 0.74 | DYRK1A (0.59) | DYRK1AEIF4EMKNK1MKNK2IRAK4 | |
| SCHEMBL16809892 | 0.71 | DYRK1A (0.55) | DYRK1AEIF4EMKNK1MKNK2IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860990-B1 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | INVENTIVA (FR) | 2022-09-14 | — | — | EP | claimed |
| CN-107803189-B | Chromatography medium using 4-amino pyrrolo [3,2-D ] pyrimidine as functional ligand | 苏州博进生物技术有限公司 | 2020-07-14 | — | — | CN | claimed |
| WO-1997049706-A1 | SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF | NOVARTIS AG (CH) | 1997-12-31 | — | — | WO | claimed |
| US-20250382305-A1 | COMPOUNDS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC THERAPEUTICS INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12128047-B2 | TLR7 agonist and pharmaceutical combination thereof for treating lung cancer | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-10-29 | — | — | US | disclosed |
| US-20240216316-A1 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | BUCK INST RES AGING (US) | 2024-07-04 | — | — | US | disclosed |
| WO-2023165570-A1 | CYCLOALKYL OR HETEROCYCLYL SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2023-09-07 | — | — | WO | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220071999-A1 | DESIGN AND DISCOVERY OF BD OXIDASE INHIBITORS FOR THE TREATMENT OF MYCOBACTERIAL DISEASES | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2022-03-10 | — | — | US | disclosed |
| US-11186575-B2 | Treatment of helicobacter pylori infections | Alber Einslein College of Medicine (US) | 2021-11-30 | — | — | US | disclosed |
| EP-3897651-A1 | DISCOVERY OF BD OXIDASE INHIBITORS FOR THE TREATMENT OF MYCOBACTERIAL DISEASES | University of Notre Dame du Lac (US) | 2021-10-27 | — | — | EP | disclosed |
| US-6040310-A | 4-aminopyrrole (3,2-d) pyrimidines as neuropeptide Y receptor antagonists | PFIZER INC. (US) | 2000-03-21 | — | — | US | disclosed |
| US-6020492-A | Deazapurine derivatives; a new class of CRF1 specific ligands | NEUROGEN CORPORATION (US) | 2000-02-01 | — | — | US | disclosed |
| US-5985848-A | EFFECTIVE INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE AND/OR NUCLEOSIDE HYDROLASES; TREATMENT AND/OR PROPHYLAXIS OF A PROTOZOAN INFECTION | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 1999-11-16 | — | — | US | disclosed |
| EP-0770080-B1 | NOVEL DEAZAPURINE DERIVATIVES; A NEW CLASS OF CRF1 SPECIFIC LIGANDS | NEUROGEN CORP (US) | 1999-07-14 | — | — | EP | disclosed |
| WO-1999007703-A1 | 4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 1999-02-18 | — | — | WO | disclosed |
| WO-1999007703-A1 | 4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 1999-02-18 | — | — | WO | disclosed |
| EP-0896822-A1 | 4-Aminopyrrole (3,2-d) pyrimidines as neuropeptide Y receptor antagonists | Pfizer Products Inc. (US) | 1999-02-17 | — | — | EP | disclosed |
| WO-1997049706-A1 | SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF | NOVARTIS AG (CH) | 1997-12-31 | — | — | WO | disclosed |
| US-5644057-A | Deazapurine derivatives; a new class of CRF1 specific ligands | NEUROGEN CORPORATION (US) | 1997-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12128047-B2 | TLR7 agonist and pharmaceutical combination thereof for treating lung cancer | TLR7, TLR9, TLR1 | DYRK1A 1072/4885PI4KA 898/4885PI4K2B 1261/4885 |
| US-20250382305-A1 | COMPOUNDS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | ATXN2, SMN1; SMN2, ATXN10 | DYRK1A 3549/4885PI4KA 3622/4885PI4K2B 2985/4885 |
| US-20240216316-A1 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | DAGLA, DAGLB, MGLL | DYRK1A 1024/4885PI4KA 3833/4885PI4K2B 3885/4885 |
| US-20220071999-A1 | DESIGN AND DISCOVERY OF BD OXIDASE INHIBITORS FOR THE TREATMENT OF MYCOBACTERIAL DISEASES | NDUFB10, NDUFB3, NDUFV3 | DYRK1A 3974/4885PI4KA 2809/4885PI4K2B 2450/4885 |
| US-11186575-B2 | Treatment of helicobacter pylori infections | MTAP, UNG, TPMT | DYRK1A 4698/4885PI4KA 2600/4885PI4K2B 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.